MedTrace Logo

Bronx Transthyretin Amyloid Cardiomyopathy Database

NCT06257485 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 476

Last updated 2026-01-09

No results posted yet for this study

Summary

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a commonly undiagnosed and potentially fatal disease. Contemporary studies on this condition often underrepresent the female gender and diverse patient populations. This registry retrospectively evaluated patients referred for 99mTc-pyrophosphate (PYP) Single Photon Emission Computed Tomography (SPECT) between 2014 and 2023 at Montefiore-Einstein in the Bronx. The patient population is racially and ethnically diverse and with a high proportion of females. Demographic, clinical (e.g. comorbidities), laboratory, echocardiographic, hospitalization, and mortality data were collected for each patient.

Conditions

  • Transthyretin Cardiac Amyloidosis
  • Transthyretin Amyloid Cardiomyopathy

Interventions

DIAGNOSTIC_TEST

99mTc-pyrophosphate Single Photon Emission Computed Tomography

All patients underwent 99mTc-pyrophosphate Single Photon Emission Computed Tomography and had a baseline echocardiogram

Sponsors & Collaborators

  • Montefiore Medical Center

    lead OTHER

Principal Investigators

  • Leandro Slipczuk, MD · Montefiore Medical Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-09-23
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06257485 on ClinicalTrials.gov